One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a case of a 74-year-old male CML patient with intracranial stenosis of the internal carotid artery developed during treatment with nilotinib successfully cured by the intracranial stent, Wingspan.
EpsteinFHFaderlSTalpazMet al.The biology of chronic myeloid leukemia. N Engl J Med1999; 341: 164–172.
2.
SattlerMGriffinJD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol2003; 40: 4–10.
3.
O’HareTDeiningerMWEideCAet al.Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res2011; 17: 212–221.
4.
BaccaraniMDeiningerMWRostiGet al.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood2013; 122: 872–884.
5.
HochhausASaglioGHughesTPet al.Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia2016; 30: 1044–1054.
6.
SaglioGKimDWIssaragrisilSet al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med2010; 362: 2251–2259.
7.
GilesFJle CoutrePDPinilla-IbarzJet al.Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia2013; 27: 107–112.
8.
KantarjianHGilesFWunderleLet al.Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med2006; 354: 2542–2551.
KimTDReaDSchwarzMet al.Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia2013; 27: 1316–1321.
13.
le CoutrePReaDAbruzzeseEet al.Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst2011; 103: 1347–1348.
14.
AichbergerKJHerndlhoferSSchernthanerGHet al.Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol2011; 86: 533–539.
15.
ValentP. Standard treatment of Ph+ CML in 2010: How, when and where not to use what BCR/ABL1 kinase inhibitor?Eur J Clin Invest2010; 40: 918–931.
16.
Chai-AdisaksophaCLamWHillisC. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A meta-analysis. Leuk Lymphoma2016; 57: 1300–1310.
17.
EmirHAlbrecht-SchgoerKHuberKet al.Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: A potential explanation for drug-induced vasculopathy in CML. Blood2013; 122: 257.
18.
ReaDMiraultTCluzeauTet al.Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica2014; 99: 1197–1203.
19.
RacilZRazgaFDrapalovaJet al.Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. Haematologica2013; 98: e124–e126.
20.
BrecciaMMuscaritoliMGentiliniFet al.Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res2007; 31: 1770–1772.
21.
DerdeynCPChimowitzMILynnMJet al.Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet2014; 383: 333–341.
22.
ChimowitzMILynnMJDerdeynCPet al.Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med2011; 365: 993–1003.
23.
ReithWBerkefeldJDietrichPet al.Diagnosis and treatment of intracranial stenoses. Clin Neuroradiol2015; 25: 307–316.
